首页> 美国卫生研究院文献>Journal of Traditional and Complementary Medicine >Proliferative activity of a blend of Echinacea angustifolia and Echinacea purpurea root extracts in human vein epithelial HeLa and QBC-939 cell lines but not in Beas-2b cell lines
【2h】

Proliferative activity of a blend of Echinacea angustifolia and Echinacea purpurea root extracts in human vein epithelial HeLa and QBC-939 cell lines but not in Beas-2b cell lines

机译:紫锥菊和紫锥菊根提取物的混合物在人静脉上皮细胞HeLa和QBC-939细胞系中的增殖活性但在Beas-2b细胞系中却没有

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Echinacea is used for its immunostimulating properties and may have a role in modulating adverse immune effects of chemotherapy (i.e., use of 5-fluorouracil (5-FU); fluorouracil and its immunosuppressive effect). Patients may seek herbal remedies such as Echinacea (Echinacea angustifolia and Echinacea purpurea) for immune stimulation. Echinacea extracts have been prescribed to supplement cancer chemotherapy for their immune-supportive effects; however, the extracts may also influence tumourgenesis. Our study aimed to determine the proliferative effect of the ethanolic blend of E. angustifolia and E. purpurea on various cancer cervical and bile duct cell lines, including HELA and QBC-939. Various cancer cells (HeLa and QBC-939) and human vein epithelial cells (HUVEC) were treated with the Echinacea blend sample that was evaporated and reconstituted in Dimethyl sulfoxide (DMSO). As the extract concentration of Echinacea was increased from 12.5 μg/mL to 25 μg/mL, there was an increase in cell inhibition up to 100%, which then reduced to 90% over the next three concentrations, 50 μg/mL, 100 μg/mL, and 200 μg/mL, in HeLa cells; further inhibitory effects were observed in QBC-939 cells, from 9% inhibition at a concentration of 25 μg/mL up to 37.96% inhibition at 100 μg/mL concentration. Moreover, this is the first study to report the growth-promoting effects of this Echinacea blend in HUVEC, up to 800% at a dose concentration of 200 μg/mL. Previous studies have suggested that chicoric acid of Echinacea spp. is responsible for the increased cell growth. The results of this study show that the hydroethanolic extract of Echinacea herbal medicine promotes the growth of HeLa cells and QBC-939 cancer cell proliferation, and may interfere with cancer treatment (i.e., chemotherapy drugs such as 5-fluorouracil and Cisplatin (DDP)). However, the Echinacea blend shows potential in neurodegenerative diseases with growth-promoting effects in HUVEC. Further animal trials (in vivo effect) measuring dose toxicology are necessary to demonstrate the interaction of this blend with body and tumor growth, and also any positive synergistic or adverse interaction with chemotherapeutic drugs listed, so as to confirm the current observation and epithelial tissue growth or regeneration in a neurodegenerative disease model.
机译:紫锥菊由于其免疫刺激特性而被使用,并且可能在调节化学疗法的不良免疫作用中起作用(即,使用5-氟尿嘧啶(5-FU);氟尿嘧啶及其免疫抑制作用)。患者可以寻求草药疗法,例如紫锥菊(Echinacea angustifolia和紫锥菊)来刺激免疫。紫锥菊提取物因其免疫支持作用而被处方用于补充癌症化疗。但是,提取物也可能影响肿瘤发生。我们的研究旨在确定大叶埃希氏菌和紫癜埃希氏菌的乙醇混合物对各种癌症宫颈和胆管细胞系(包括HELA和QBC-939)的增殖作用。用紫锥菊混合样品处理各种癌细胞(HeLa和QBC-939)和人静脉上皮细胞(HUVEC),将其混合后在二甲基亚砜(DMSO)中蒸发。随着紫锥菊提取物浓度从12.5μg/ mL增加到25μg/ mL,细胞抑制作用增加到100%,然后在接下来的三个浓度50μg/ mL,100μg中降低到90% / mL和200μg/ mL,在HeLa细胞中;在QBC-939细胞中观察到了进一步的抑制作用,从浓度为25μg/ mL时的抑制率为9%到浓度为100μg/ mL时的抑制率为37.96%。此外,这是第一项报道这种紫锥菊混合物在HUVEC中的促生长作用的研究,剂量为200μg/ mL时可达800%。先前的研究表明紫锥菊的菊苣酸。负责增加细胞的生长。这项研究的结果表明,紫锥菊属植物的乙醇提取物可促进HeLa细胞的生长和QBC-939癌细胞的增殖,并可能会干扰癌症的治疗(例如5-氟尿嘧啶和顺铂(DDP)等化学治疗药物) 。然而,紫锥菊混合物在神经退行性疾病中显示出潜力,对HUVEC具有促进生长的作用。进一步的动物实验(体内作用)需要测量剂量毒理学,以证明这种混合物与人体和肿瘤生长的相互作用,以及与所列化学治疗药物的任何正协同或不利相互作用,以证实目前的观察结果和上皮组织生长或神经退行性疾病模型中的再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号